Navigation Links
Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Date:10/1/2009

NEW YORK, Oct. 1 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid X receptor (FXR) agonist INT-747 has met the primary endpoint of improved insulin sensitization in a 6 week double blind, placebo controlled trial in type 2 diabetic patients with nonalcoholic fatty liver disease (NAFLD).

By employing a euglycemic insulin clamp procedure, the study demonstrated that a single oral daily dose of INT-747 statistically significantly improved glucose disposal rate, consistent with improved hepatic and peripheral insulin sensitivity. Furthermore, patients treated with INT-747 demonstrated statistically significant weight loss and improved biochemical markers of liver function. The compound was well tolerated at the doses tested, with side effects similar to placebo.

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "INT-747 therapy generated several clinically meaningful signals in this first proof of concept study, validating the mechanism of action of FXR activation that we and other groups have described preclinically." Dr. Shapiro is presenting the results of the trial on Friday, Oct. 2, in a plenary session at the European Association for the Study of Diabetes (EASD) annual meeting.

Insulin resistance is an important driver of liver fibrosis, the progressive scarring that can lead to cirrhosis. Based on INT-747's ability to improve insulin sensitivity and other important parameters of liver function in this patient population, Intercept is planning to initiate a Phase II trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. There are an estimated 5 million or more NASH patients in the United States alone with no effective therapeutics currently available.

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Intercept's lead drug candidate, the FXR agonist INT-747, is currently being advanced for chronic liver disease indications. The company's next candidate in the pipeline, INT-777, is a selective TGR5 agonist being advanced to an IND, projected for the second quarter of 2010.

For more information about Intercept, please go to www.interceptpharma.com, and for information about Intercept's lead investor, Genextra S.p.A., please go to www.genextra.it.

SOURCE Intercept Pharmaceuticals, Inc.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
4. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
5. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
6. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
7. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
8. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):